Dive into the complex landscape of developmental disorders with a comprehensive look at managing Trisomy 21, Fetal Alcohol Spectrum Disorders (FASD), and clinical dysmorphology. We explore the psychiatric comorbidities of Down syndrome, offering evidence-based pharmacologic strategies for treating depression, anxiety, and ADHD while challenging implicit biases that limit patient potential. Expert insights reveal why over 85% of FASD cases are misdiagnosed and provide practical screening techniques to identify alcohol-related neurodevelopmental deficits that lack physical markers. The discussion extends to recognizing subtle genetic signs, such as those in 22q deletion syndrome, to help clinicians look beyond behavioral symptoms for underlying causes. We also evaluate new research on using topiramate to mitigate antipsychotic-induced weight gain and  ...